You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.

    SBC: Shift Pharmaceuticals Holdings, Inc.            Topic: 106

    Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.

    SBC: Antiger Therapeutics Inc.            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections

    SBC: FIMBRION THERAPEUTICS INC            Topic: NIAID

    1 ABSTRACT. Urinary tract infections (UTI) are extremely common world-wide, and can lead to serious2 complications, including renal scarring and urosepsis. Standard-of-care treatments rely on antibiotics: empiric3 treatment for uncomplicated UTI (uUTI), broad-spectrum for complicated UTI (cUTI), and long-term prophylaxis4 for recurrent UTI (rUTI). This constant antibiotic exposure not only disrupt ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Novel Approach to Immunotherapy.

    SBC: CADRE BIOSCIENCE, LLC            Topic: NCI

    PROJECT SUMMARY/ABSTRACT. This phase 1 SBIR project proposes development of a new type of drug to improve the treatment of cancer. This new approach offers potential in many forms of the disease, including breast cancer, which is second only to cancer of the lung in terms of mortality. In particular, triple negative breast cancer (TNBC) is very challenging to treat as there are fewer therapeutic o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Low-Dose Magneto-Thrombolysis to Expand Stroke Care

    SBC: UNANDUP, LLC            Topic: 106

    Acute ischemic stroke (AIS) results from a blood clot in the neurovasculature and is a leading cause of death and neurological disability in the United States (US). AIS impacts more than 700,000 Americans annually, with a 65% chance of death or severe disability. By 2030, it is expected that the AIS economic burden will exceed $180B in the US alone.Standard AIS therapies include FDA-approved throm ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Framewise Integrated Real-Time MRI Monitoring (FIRMM) software commercialization readiness for clinical care

    SBC: TURING MEDICAL TECHNOLOGIES INC            Topic: 102

    Project Abstract/SummaryMotion related artifacts are a significant source of cost to the healthcare system. With over 12,000 MRI scanners in the U.S. and estimates that $434,000 are lost per scanner each year, motion in MRIs is costing our health care system approximately $4B yearly. Our FDA-cleared software solution Framewise Integrated Real- Time MRI Monitoring (FIRMM) mitigates data lost due to ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a blood fatty acid-based algorithm as an early predictor of insulin resistance: Applying machine learning to harmonized data from prospective cohort studies

    SBC: OMEGAQUANT ANALYTICS, LLC.            Topic: 200

    Project Summary Metabolic diseases, such as Metabolic Syndrome (MetSyn) and type 2 diabetes (T2DM) affect ~37% and ~10% of Americans, respectively, with a substantial impact on the health, quality of life and financial security of these individuals. Without the means to identify high risk individuals conveniently and cheaply, many will find care too little and too late: more than 80% of individual ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Group B Streptococcus bioconjugate vaccine

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide. GBS neonatal disease manifests as early onset invasive disease, defined as disease between birth and 6 days of life, or late onset invasive disease, defined as disease occurring between 7 and 89 days. In some instances, early onset disease i ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis

    SBC: FIMBRION THERAPEUTICS INC            Topic: R

    Project Summary/Abstract Tuberculosis (TB), caused by infection with the bacterium Mycobacterium tuberculosis (Mtb), is a leading cause of mortality due to infection, globally. In 2020, 10 million people were newly diagnosed with TB and 1.5 million people died from the disease. As efforts to treat TB expand, the prevalence of infections caused by drug-resistant Mtb strains (DR-TB) that are resista ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government